Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry

Acta Oncologica

Volumn 55, Issue 4, 2016, Pages 480-485

  Tomita, Yoko ^a   Karapetis, Christos S ^b   Ullah, Shahid ^c   Townsend, Amanda R ^a   Roder, David ^d   Beeke, Carol ^b   Roy, Amitesh C ^b   Padbury, Rob ^b   Price, Timothy J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; K RAS PROTEIN; PANITUMUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; AUSTRALIAN; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TUMOR LOCALIZATION; ADOLESCENT; ADULT; COLORECTAL NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; REGISTER; SOUTH AUSTRALIA; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SOUTH AUSTRALIA; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84958054447     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1117135     Document Type: Article

References (25)

1. Australian Institute of Health and Welfare. Cancer in Australia: An overview 2014. Canberra: AIHW; 2014.
2. Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007; 13: 3806-15.
3. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-83.
4. The Pharmaceutical Benefits Scheme. Bevacizumab, solution for I.V. infusion, 100mg in 4 mL, 400mg in 16 mL, Avastin, July 2008.Canberra: Commonweatlth of Australia; 2008 [updated 31st October 2008; cited 2015 27th October]. Available from: Http: //www.pbs.gov. au/info/industry/listing/elements/pbac-meetings/psd/2008-07/pbacpsd- bevacizumab-july08
5. The Pharmaceutical Benefits Scheme. CETUXIMAB, solution for I.V. infusion, 100mg in 20 mL and 500mg in 100 mL, Erbitux. Canberra: Commonwealth of Australia; 2010 [updated 19th October 2010; cited 2015 27th October]. Available from: Http: //www.pbs.gov.au/ info/industry/listing/elements/pbac-meetings/psd/2010-07/pbac-psd- Cetuximab-july10
6. The Pharmaceutical Benefits Scheme. Panitumumab; 100 mg/5 mL injection, 1 x 5 mL vial, 400 mg/20 mL injection, 1 x 20 mL vial; Vectibix. Canberra: Commonwealth of Australia; 2015 [updated 3rd October 2010; cited 2015 27th October]. Available from: Http: // www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2015- 03/Files/panitumumab-psd-march-2015.pdf
7. The Pharmaceutical Benefits Scheme. A-Z medicine listing. Canberra: Commonwealth of Australia; [cited 2015 27th October]. Available from: Http: //www.pbs.gov.au/browse/medicine-listing
8. Neo EL, Beeke C, Price T, Maddern G, Karapetis C, Luke C, et al. South Australian clinical registry for metastatic colorectal cancer. ANZ J Surg 2011; 81: 352-7.
9. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.
10. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 1346-55.
11. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, Mckinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-Analysis of randomized, controlled trials. Ann Oncol 2015; 26: 13-21.
12. Yeung Y, Tebbutt NC. Bevacizumab in colorectal cancer: Current and future directions. Exp Rev Anticancer Ther 2012; 12: 1263-73.
13. Sclafani F, Cunningham D. Bevacizumab in elderly patients with metastatic colorectal cancer. J Geriatr Oncol 2014; 5: 78-88.
14. Gibbs P. HOTT Pharmacy Presentation: Update on Colorectal Cncer. Sydney, Australia: 2013 [cited 2015 27th October]. Available from: Http: //www.aph.gov.au/DocumentStore.ashx?id=69ce0d4e-b7ed-46a6- bb9f-0c899f710af9
15. Meyerhardt JA, Li L, Sanoff HK, Carpenter Wt Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 2012; 30: 608-15.
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Eng J Med 2004; 350: 2335-42.
17. Kabbinavar FF, Schulz J, Mccleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in firstline metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-705.
18. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009; 115: 4679-87.
19. Jonker DJ, O'callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. New Eng J Med 2007; 357: 2040-8.
20. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014; 15: 569-79.
21. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-12.
22. Australian New Zealand Clinical Trials. Registry Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer (CRC) with either KRAS WT or G13D mutation. Camperdown, Australia: 2012 [cited 2015 27th October]. Available from: Https: //www.anzctr.org.au/Trial/ Registration/TrialReview.aspx?id=362339
23. Young JP, Win AK, Rosty C, Flight I, Roder D, Young GP, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: Report and review. J Gastroenter Hepatol 2015; 30: 6-13.
24. Weiss JM, Pfau PR, O'connor ES, King J, Loconte N, Kennedy G, et al. Mortality by stage for right- versus left-sided colon cancer: Analysis of surveillance, epidemiology, and end results-Medicare data. J Clin Oncol 2011; 29: 4401-9.
25. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H, et al. Comparison of 17,641 patients with right- And left-sided colon cancer: Differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rect 2010; 53: 57-64.